Your browser doesn't support javascript.
loading
Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis.
Shaffer, Seth R; Traboulsi, Cindy; Krugliak Cleveland, Noa; Rubin, David T.
Afiliación
  • Shaffer SR; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
  • Traboulsi C; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
  • Krugliak Cleveland N; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
  • Rubin DT; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
ACG Case Rep J ; 8(5): e00604, 2021 May.
Article en En | MEDLINE | ID: mdl-34007860
ABSTRACT
We have demonstrated the effectiveness and safety of combining cyclosporine and vedolizumab to treat ulcerative colitis (UC). We present 2 cases of hospitalized acute severe UC who had failed therapy with antitumor necrosis factor and vedolizumab and were treated successfully with induction cyclosporine and safely bridged to ustekinumab maintenance therapy. Both patients have avoided colectomy. There were no adverse events. We propose this novel treatment combination in medically resistant acute severe UC.